AI
C3.ai, Inc.
Information Technology Services
Market Cap$1.28B
5Y Perf.-79.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AI vs PRCT
Revenue, margins, valuation, and 5-year total return — side by side.
PRCT
PROCEPT BioRobotics Corporation
Medical - Devices
Market Cap$1.45B
5Y Perf.-33.3%
AI vs PRCT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AI | PRCT |
|---|---|---|
| Industry | Information Technology Services | Medical - Devices |
| Market Cap | $1.28B | $1.45B |
| Revenue (TTM) | $307M | $322M |
| Net Income (TTM) | $-435M | $-102M |
| Gross Margin | 43.5% | 63.0% |
| Operating Margin | -151.7% | -33.9% |
| Total Debt | $5M | $52M |
| Cash & Equiv. | $164M | $287M |
AI vs PRCT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AI
PRCT
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| C3.ai, Inc. (AI) | 100 | 20.7 | -79.3% |
| PROCEPT BioRobotics… (PRCT) | 100 | 66.7 | -33.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AI vs PRCT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRCT leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
AI
C3.ai, Inc.
The Defensive Pick
AI is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.53, Low D/E 0.6%, current ratio 6.86x
Best for: sleep-well-at-night
PRCT
PROCEPT BioRobotics Corporation
The Income Pick
PRCT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.23
- Rev growth 37.2%, EPS growth 1.7%, 3Y rev CAGR 60.1%
- -39.3% 10Y total return vs AI's -82.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRCT | 37.2% revenue growth vs AI's 25.3% |
| Quality / Margins | PRCT | -31.8% margin vs AI's -141.4% |
| Stability / Safety | PRCT | Beta 1.23 vs AI's 2.53 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PRCT | -52.1% vs AI's -57.0% |
| Efficiency (ROA) | PRCT | -20.3% ROA vs AI's -48.5%, ROIC -55.7% vs -35.1% |
AI vs PRCT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
AI vs PRCT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRCTLAGGINGAI
AIC3.ai, Inc.
1leads
PRCTPROCEPT BioRobotics C…
4leads
6 Total Categories
CATEGORYLEADERvs AIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRCT6/6
Valuation MetricsMultiples, price ratios, and targets
AI2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRCT5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRCT6/6
Risk & VolatilityBeta, volatility, and downside exposure
PRCT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRCT leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRCT and AI operate at a comparable scale, with $322M and $307M in trailing revenue. PRCT is the more profitable business, keeping -31.8% of every revenue dollar as net income compared to AI's -141.4%. On growth, PRCT holds the edge at +20.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AIC3.ai, Inc. | PRCTPROCEPT BioRoboti… |
|---|---|---|
| RevenueTrailing 12 months | $307M | $322M |
| EBITDAEarnings before interest/tax | -$455M | -$102M |
| Net IncomeAfter-tax profit | -$435M | -$102M |
| Free Cash FlowCash after capex | -$127M | -$81M |
| Gross MarginGross profit ÷ Revenue | +43.5% | +63.0% |
| Operating MarginEBIT ÷ Revenue | -151.7% | -33.9% |
| Net MarginNet income ÷ Revenue | -141.4% | -31.8% |
| FCF MarginFCF ÷ Revenue | -41.3% | -25.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -46.1% | +20.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -53.2% | -24.4% |
PRCT leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
AI leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | AIC3.ai, Inc. | PRCTPROCEPT BioRoboti… |
|---|---|---|
| Market CapShares × price | $1.3B | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -4.28x | -14.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.30x | 4.70x |
| Price / BookPrice ÷ Book value/share | 1.48x | 3.86x |
| Price / FCFMarket cap ÷ FCF | — | — |
AI leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
PRCT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
PRCT delivers a -27.7% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-60 for AI. AI carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRCT's 0.14x. On the Piotroski fundamental quality scale (0–9), PRCT scores 5/9 vs AI's 3/9, reflecting solid financial health.
| Metric | AIC3.ai, Inc. | PRCTPROCEPT BioRoboti… |
|---|---|---|
| ROE (TTM)Return on equity | -60.4% | -27.7% |
| ROA (TTM)Return on assets | -48.5% | -20.3% |
| ROICReturn on invested capital | -35.1% | -55.7% |
| ROCEReturn on capital employed | -35.5% | -22.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.14x |
| Net DebtTotal debt minus cash | -$160M | -$235M |
| Cash & Equiv.Liquid assets | $164M | $287M |
| Total DebtShort + long-term debt | $5M | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | -30.92x |
PRCT leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRCT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRCT five years ago would be worth $6,066 today (with dividends reinvested), compared to $1,701 for AI. Over the past 12 months, PRCT leads with a -52.1% total return vs AI's -57.0%. The 3-year compound annual growth rate (CAGR) favors PRCT at -2.7% vs AI's -20.7% — a key indicator of consistent wealth creation.
| Metric | AIC3.ai, Inc. | PRCTPROCEPT BioRoboti… |
|---|---|---|
| YTD ReturnYear-to-date | -30.3% | -17.3% |
| 1-Year ReturnPast 12 months | -57.0% | -52.1% |
| 3-Year ReturnCumulative with dividends | -50.2% | -7.8% |
| 5-Year ReturnCumulative with dividends | -83.0% | -39.3% |
| 10-Year ReturnCumulative with dividends | -82.2% | -39.3% |
| CAGR (3Y)Annualised 3-year return | -20.7% | -2.7% |
PRCT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
PRCT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRCT is the less volatile stock with a 1.23 beta — it tends to amplify market swings less than AI's 2.53 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRCT currently trades 38.1% from its 52-week high vs AI's 31.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIC3.ai, Inc. | PRCTPROCEPT BioRoboti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.53x | 1.23x |
| 52-Week HighHighest price in past year | $30.24 | $66.85 |
| 52-Week LowLowest price in past year | $7.67 | $19.35 |
| % of 52W HighCurrent price vs 52-week peak | +31.7% | +38.1% |
| RSI (14)Momentum oscillator 0–100 | 59.9 | 50.9 |
| Avg Volume (50D)Average daily shares traded | 5.5M | 1.7M |
PRCT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AI as "Hold" and PRCT as "Buy". Consensus price targets imply 74.9% upside for PRCT (target: $45) vs -22.8% for AI (target: $7).
| Metric | AIC3.ai, Inc. | PRCTPROCEPT BioRoboti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $7.40 | $44.50 |
| # AnalystsCovering analysts | 28 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRCT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AI leads in 1 (Valuation Metrics).
Best OverallPROCEPT BioRobotics Corpora… (PRCT)Leads 4 of 6 categories
Loading custom metrics...
AI vs PRCT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AI or PRCT a better buy right now?
For growth investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger pick with 37.
2% revenue growth year-over-year, versus 25. 3% for C3. ai, Inc. (AI). Analysts rate PROCEPT BioRobotics Corporation (PRCT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AI or PRCT?
Over the past 5 years, PROCEPT BioRobotics Corporation (PRCT) delivered a total return of -39.
3%, compared to -83. 0% for C3. ai, Inc. (AI). Over 10 years, the gap is even starker: PRCT returned -39. 3% versus AI's -82. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AI or PRCT?
By beta (market sensitivity over 5 years), PROCEPT BioRobotics Corporation (PRCT) is the lower-risk stock at 1.
23β versus C3. ai, Inc. 's 2. 53β — meaning AI is approximately 105% more volatile than PRCT relative to the S&P 500. On balance sheet safety, C3. ai, Inc. (AI) carries a lower debt/equity ratio of 1% versus 14% for PROCEPT BioRobotics Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AI or PRCT?
By revenue growth (latest reported year), PROCEPT BioRobotics Corporation (PRCT) is pulling ahead at 37.
2% versus 25. 3% for C3. ai, Inc. (AI). On earnings-per-share growth, the picture is similar: C3. ai, Inc. grew EPS 4. 3% year-over-year, compared to 1. 7% for PROCEPT BioRobotics Corporation. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AI or PRCT?
PROCEPT BioRobotics Corporation (PRCT) is the more profitable company, earning -31.
0% net margin versus -74. 2% for C3. ai, Inc. — meaning it keeps -31. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRCT leads at -33. 7% versus -83. 4% for AI. At the gross margin level — before operating expenses — PRCT leads at 63. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AI or PRCT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AI or PRCT better for a retirement portfolio?
For long-horizon retirement investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
23)). C3. ai, Inc. (AI) carries a higher beta of 2. 53 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRCT: -39. 3%, AI: -82. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AI and PRCT?
These companies operate in different sectors (AI (Technology) and PRCT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(AI: -46.1% · PRCT: 20.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.